Experimental laboratory biomarkers in multiple sclerosis

Wien Med Wochenschr. 2022 Nov;172(15-16):346-358. doi: 10.1007/s10354-022-00920-7. Epub 2022 Mar 7.

Abstract

Background: Multiple sclerosis (MS) is a chronic autoimmune disorder of the central nervous system; the cause of this condition remains unknown. Researchers have analyzed different biomarkers related to MS. Here, experimental laboratory biomarkers for MS are identified and analyzed.

Methods: The current study examined articles investigating biomarkers for MS. Records were obtained from the PubMed, LILACS, and EBSCO databases using an identical search strategy and terms that included "multiple sclerosis," "MS," and "biomarkers." In the current review, we also focus on lesser known biomarkers that have not yet been established for use in clinical practice.

Results: Previous studies have explored molecular substances that may help diagnose MS and manage its adverse effects. Commonly studied factors include neurofilaments, sCD163, CXCL13, NEO, NF‑L, OPN, B cells, T cells, and integrin-binding proteins.

Conclusions: Interactions between environmental and genetic factors have been implicated in the development of MS. Previous investigations have identified a wide range of biomarkers that can be used for diagnosis and disease management. These molecules and their associated studies provide vital insight and data to help primary physicians improve clinical and health outcomes for MS patients.

Keywords: Biomarkers; Biomarkers in multiple sclerosis; Development; Disease activity; Progression.

Publication types

  • Review

MeSH terms

  • Biomarkers
  • Humans
  • Integrins
  • Multiple Sclerosis* / diagnosis

Substances

  • Biomarkers
  • Integrins